Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols HTT and SYMPK	Name 1 huntingtin	Name2 symplekin scaffold protein	Pathway 1 Regulation of MECP2 expression and activity	Pathway 2 Transport of Mature mRNA Derived from an Intronless Transcript mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs	Drugs 1 Copper	Drugs 2	Diseases 1 Huntington's disease (HD)	Diseases 2
Novel Novel	Symbols ID3 and MSGN1	Name 1 inhibitor of DNA binding 3	Name2 mesogenin 1	Pathway 1 NGF-stimulated transcription	Pathway 2 Formation of paraxial mesoderm Somitogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols IGF1R and VPS45	Name 1 insulin like growth factor 1 receptor	Name2 vacuolar protein sorting 45 homolog	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Intra-Golgi traffic SARS-CoV-2 modulates autophagy Factors involved in megakaryocyte development and platelet production	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IGF1R and DUSP14	Name 1 insulin like growth factor 1 receptor	Name2 dual specificity phosphatase 14	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IGF1R and STYX	Name 1 insulin like growth factor 1 receptor	Name2 serine/threonine/tyrosine interacting protein	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel Novel	Symbols IGF1R and IGF2	Name 1 insulin like growth factor 1 receptor	Name2 insulin like growth factor 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Platelet degranulation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2 Russell-Silver syndrome; Silver-Russell syndrome Beckwith-Wiedemann syndrome Adrenal carcinoma
Novel Novel	Symbols IRS1 and PLCG2	Name 1 insulin receptor substrate 1	Name2 phospholipase C gamma 2	Pathway 1 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Pathway 2 GPVI-mediated activation cascade Toll Like Receptor 4 (TLR4) Cascade Synthesis of IP3 and IP4 in the cytosol Generation of second messenger molecules Role of phospholipids in phagocytosis DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization CLEC7A (Dectin-1) signaling CLEC7A (Dectin-1) signaling Dectin-2 family Dectin-2 family Erythropoietin activates Phospholipase C gamma (PLCG) FCGR3A-mediated IL10 synthesis Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols IL1A and IL1RAP	Name 1 interleukin 1 alpha	Name2 interleukin 1 receptor accessory protein	Pathway 1 Senescence-Associated Secretory Phenotype (SASP) Interleukin-1 processing Pyroptosis Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Interleukin-1 signaling Purinergic signaling in leishmaniasis infection	Pathway 2	Drugs 1 Rilonacept	Drugs 2	Diseases 1 Graft-versus-host disease	Diseases 2
Novel Novel	Symbols JAK2 and STAM2	Name 1 Janus kinase 2	Name2 signal transducing adaptor molecule 2	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	Pathway 2 EGFR downregulation Ub-specific processing proteases Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell RHOU GTPase cycle Endosomal Sorting Complex Required For Transport (ESCRT)	Drugs 1 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Drugs 2	Diseases 1 Polycythemia vera	Diseases 2
Novel Novel	Symbols BYSL and CDC23	Name 1 bystin like	Name2 cell division cycle 23	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and L3MBTL3	Name 1 bystin like	Name2 L3MBTL histone methyl-lysine binding protein 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and TRIM38	Name 1 bystin like	Name2 tripartite motif containing 38	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Interferon gamma signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and RALY	Name 1 bystin like	Name2 RALY heterogeneous nuclear ribonucleoprotein	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols BYSL and PRICKLE1	Name 1 bystin like	Name2 prickle planar cell polarity protein 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Asymmetric localization of PCP proteins	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
Novel Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and ITSN2	Name 1 Cbl proto-oncogene	Name2 intersectin 2	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis RHOU GTPase cycle	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and EPHB6	Name 1 Cbl proto-oncogene	Name2 EPH receptor B6	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 EPH-Ephrin signaling EPH-Ephrin signaling EPHB-mediated forward signaling EPHB-mediated forward signaling Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells	Drugs 1	Drugs 2 Fostamatinib	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel Novel	Symbols CBL and CD19	Name 1 Cbl proto-oncogene	Name2 CD19 molecule	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1	Drugs 2 Coltuximab ravtansine Blinatumomab Depatuxizumab mafodotin Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel Loncastuximab tesirine Lisocabtagene maraleucel	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
Novel Novel	Symbols KRT18 and CCHCR1	Name 1 keratin 18	Name2 coiled-coil alpha-helical rod protein 1	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols KRT18 and RHPN2	Name 1 keratin 18	Name2 rhophilin Rho GTPase binding protein 2	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2 RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins RHOA GTPase cycle RHOB GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols HTT and SYMPK	Name 1 huntingtin	Name2 symplekin scaffold protein	Pathway 1 Regulation of MECP2 expression and activity	Pathway 2 Transport of Mature mRNA Derived from an Intronless Transcript mRNA 3'-end processing Processing of Capped Intron-Containing Pre-mRNA RNA Polymerase II Transcription Termination Processing of Intronless Pre-mRNAs	Drugs 1 Copper	Drugs 2	Diseases 1 Huntington's disease (HD)	Diseases 2
Novel	Symbols ID3 and MSGN1	Name 1 inhibitor of DNA binding 3	Name2 mesogenin 1	Pathway 1 NGF-stimulated transcription	Pathway 2 Formation of paraxial mesoderm Somitogenesis	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols IGF1R and VPS45	Name 1 insulin like growth factor 1 receptor	Name2 vacuolar protein sorting 45 homolog	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Intra-Golgi traffic SARS-CoV-2 modulates autophagy Factors involved in megakaryocyte development and platelet production	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IGF1R and DUSP14	Name 1 insulin like growth factor 1 receptor	Name2 dual specificity phosphatase 14	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IGF1R and STYX	Name 1 insulin like growth factor 1 receptor	Name2 serine/threonine/tyrosine interacting protein	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2
Novel	Symbols IGF1R and IGF2	Name 1 insulin like growth factor 1 receptor	Name2 insulin like growth factor 2	Pathway 1 Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Extra-nuclear estrogen signaling Respiratory syncytial virus (RSV) attachment and entry	Pathway 2 Platelet degranulation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) IRS-related events triggered by IGF1R SHC-related events triggered by IGF1R Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	Drugs 1 Insulin human Insulin lispro Insulin glargine Insulin pork Mecasermin Insulin aspart Insulin detemir Insulin glulisine Phosphoaminophosphonic Acid-Adenylate Ester ATL1101 XL228 rhIGFBP-3 Linsitinib Teprotumumab (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE Nandrolone decanoate Somatrem Insulin beef Insulin degludec Insulin argine Insulin peglispro Insulin tregopil Dalotuzumab Cixutumumab Brigatinib Mecasermin rinfabate BMS-754807 KW-2450 free base	Drugs 2	Diseases 1 Synovial sarcoma Malignant pleural mesothelioma	Diseases 2 Russell-Silver syndrome; Silver-Russell syndrome Beckwith-Wiedemann syndrome Adrenal carcinoma
Novel	Symbols IRS1 and PLCG2	Name 1 insulin receptor substrate 1	Name2 phospholipase C gamma 2	Pathway 1 PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	Pathway 2 GPVI-mediated activation cascade Toll Like Receptor 4 (TLR4) Cascade Synthesis of IP3 and IP4 in the cytosol Generation of second messenger molecules Role of phospholipids in phagocytosis DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization CLEC7A (Dectin-1) signaling CLEC7A (Dectin-1) signaling Dectin-2 family Dectin-2 family Erythropoietin activates Phospholipase C gamma (PLCG) FCGR3A-mediated IL10 synthesis Potential therapeutics for SARS Signaling by CSF1 (M-CSF) in myeloid cells Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols IL1A and IL1RAP	Name 1 interleukin 1 alpha	Name2 interleukin 1 receptor accessory protein	Pathway 1 Senescence-Associated Secretory Phenotype (SASP) Interleukin-1 processing Pyroptosis Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Interleukin-1 signaling Purinergic signaling in leishmaniasis infection	Pathway 2	Drugs 1 Rilonacept	Drugs 2	Diseases 1 Graft-versus-host disease	Diseases 2
Novel	Symbols JAK2 and STAM2	Name 1 Janus kinase 2	Name2 signal transducing adaptor molecule 2	Pathway 1 Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	Pathway 2 EGFR downregulation Ub-specific processing proteases Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell RHOU GTPase cycle Endosomal Sorting Complex Required For Transport (ESCRT)	Drugs 1 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Drugs 2	Diseases 1 Polycythemia vera	Diseases 2
Novel	Symbols BYSL and CDC23	Name 1 bystin like	Name2 cell division cycle 23	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Inactivation of APC/C via direct inhibition of the APC/C complex APC/C:Cdc20 mediated degradation of Cyclin B Autodegradation of Cdh1 by Cdh1:APC/C APC/C:Cdc20 mediated degradation of Securin APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Cdc20:Phospho-APC/C mediated degradation of Cyclin A Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase APC/C:Cdc20 mediated degradation of mitotic proteins Phosphorylation of the APC/C APC-Cdc20 mediated degradation of Nek2A Separation of Sister Chromatids Senescence-Associated Secretory Phenotype (SASP) Assembly of the pre-replicative complex CDK-mediated phosphorylation and removal of Cdc6 Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and L3MBTL3	Name 1 bystin like	Name2 L3MBTL histone methyl-lysine binding protein 3	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and TRIM38	Name 1 bystin like	Name2 tripartite motif containing 38	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Interferon gamma signaling	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and RALY	Name 1 bystin like	Name2 RALY heterogeneous nuclear ribonucleoprotein	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols BYSL and PRICKLE1	Name 1 bystin like	Name2 prickle planar cell polarity protein 1	Pathway 1 Major pathway of rRNA processing in the nucleolus and cytosol	Pathway 2 Asymmetric localization of PCP proteins	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
Novel	Symbols CBL and LRIG1	Name 1 Cbl proto-oncogene	Name2 leucine rich repeats and immunoglobulin like domains 1	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Signaling by EGFR Negative regulation of MET activity Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and ITSN2	Name 1 Cbl proto-oncogene	Name2 intersectin 2	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis RHOU GTPase cycle	Drugs 1	Drugs 2	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and EPHB6	Name 1 Cbl proto-oncogene	Name2 EPH receptor B6	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 EPH-Ephrin signaling EPH-Ephrin signaling EPHB-mediated forward signaling EPHB-mediated forward signaling Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells	Drugs 1	Drugs 2 Fostamatinib	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2
Novel	Symbols CBL and CD19	Name 1 Cbl proto-oncogene	Name2 CD19 molecule	Pathway 1 Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants	Pathway 2 PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Drugs 1	Drugs 2 Coltuximab ravtansine Blinatumomab Depatuxizumab mafodotin Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel Loncastuximab tesirine Lisocabtagene maraleucel	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
Novel	Symbols KRT18 and CCHCR1	Name 1 keratin 18	Name2 coiled-coil alpha-helical rod protein 1	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols KRT18 and RHPN2	Name 1 keratin 18	Name2 rhophilin Rho GTPase binding protein 2	Pathway 1 Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Pathway 2 RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins RHOA GTPase cycle RHOB GTPase cycle	Drugs 1	Drugs 2	Diseases 1	Diseases 2

Page 37 out of 98 pages

Search Results : Cancer